Results obtained with RapiTest THC (One Step delta 9-Tetrahydrocannabinol Test), RapiTest MOP (One Step Morphine Test), RapiTest MET (One Step Methamphetamine Test), and RapiTest COC (One Step Cocaine Test) were compared with the results obtained with Emit d.a.u. and with gas chromatographic-mass spectrometric (GC-MS) methods. In all, 81 urine samples taken from specimens submitted for routine analysis in the Laboratory of Pharmacology and Toxicology were analyzed. Samples were screened with Emit, reanalyzed by RapiTests, and quantitated using GC-MS methods. Both positive and negative urine samples were tested. The results obtained with RapiTests correlated well with the Emit d.a.u. and GC-MS data when operating above the cutoff concentrations specified for these methods. RapiTest MOP was found to have crossreactivity with codeine and ethylmorphine, and RapiTest MET crossreacted with amphetamine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jat/21.1.49 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Determination of designer drug cross-reactivity on five commercial immunoassay screening kits.
J Anal Toxicol
March 2015
Division of Forensic Toxicology, Armed Forces Medical Examiner System, Dover AFB, DE, USA.
The detection of new designer drugs is often a difficult issue in forensic urine drug testing as immunoassays are the primary screening methodology for drugs of abuse in many of these laboratories. Cross-reactivity of compounds with immunoassay kits can either aid or complicate the detection of a variety of drug and drug metabolites. For instance, emerging designer drugs that share structural similarities to amphetamines and phencyclidine (PCP) have the potential to cross-react with assays designed to detect these compounds.
View Article and Find Full Text PDFDetectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse.
Drug Test Anal
May 2014
Department of Laboratory Medicine, section of Clinical Pharmacology, Karolinska University Hospital, Sweden.
The increasing number of new psychoactive substances made available for recreational drug use has created a challenge for clinical toxicology and drug testing laboratories. As a consequence, the routine immunoassay drug testing may become less effective due to an increased occurrence of false negative and false positive screening results. This work aimed to extend the knowledge about analytical cross-reactivity of new substances in selected CEDIA, EMIT, and KIMS immunoassays for drugs-of-abuse screening.
View Article and Find Full Text PDFCross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View™, and the Emit® assays for use in drug enforcement.
Forensic Sci Int
April 2012
Forensic Science Laboratory, Osaka Prefectural Police Headquarters, 1-3-18 Hommachi, Chuo-ward, Osaka 541-0053, Japan.
Cross-reactivities of 76 kinds of phenethylamine-type designer drugs and related compounds to the urine drug tests Instant-View ™ (IV) (the Methamphetamine (MA) test, the Amphetamine 300 test, and the MDMA test) have been investigated. An on-site urine test kit consisting of these three IV tests has been evaluated for the on-site screening of MA users, and the kit has been found to have satisfactory specificity for drug enforcement purposes by separately detecting both MA and its metabolite amphetamine. The cross-reactivity profiles of Emit(®) II Plus Amphetamines Assay, Emit(®) II Plus Ecstasy assay, and Emit(®) d.
View Article and Find Full Text PDFPerformance of three point-of-care urinalysis test devices for drugs of abuse and therapeutic drugs applied in the emergency department.
J Emerg Med
June 2012
Department of Pharmacy, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
Background: Point-of-care tests for toxicological screening of patients for drugs of abuse and therapeutic drugs may be helpful in the emergency department (ED) to assist in a rapid diagnosis.
Objectives: In this prospective study, the performance of TesTcard9® (Varian; Middelburg, Netherlands), Syva RapidTest d.a.
[Blood screening of benzodiazepines and tricyclic antidepressants. Results of 5 years of interhospital controls].
Acta Clin Belg
October 2006
Laboratoire des Urgences Biochimiques et Toxicologiques, Centre hospitalier Lyon Sud, 165 chemin du grand Revoyet, 69495 Pierre-benite, France.
Pro bio Qual Association of Lyon have proposed a control which include the control for detecting benzodiazepines (BZD) and tricyclic antidepressants (ADT) since 2000. With this control, we have evaluated the specificity and the sensitivity of techniques used. We have tested the maprotiline reactivity too (tetracyclic antidepressant).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!